Related Experiment Videos
Two-stage adaptive design for clinical trials with survival data
Gang Li1, Weichung J Shih, Yining Wang
1Clinical Biostatistics, Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey, USA. ligang8844@yahoo.com
Journal of Biopharmaceutical Statistics
|July 19, 2005
Summary
This study introduces a two-stage adaptive design for long-term clinical trials with survival endpoints. It enables early trial termination or enrollment adjustments based on interim data analysis, optimizing resource allocation.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Survival Analysis
Background:
- Long-term clinical trials require continuous monitoring of patient enrollment, compliance, and treatment effects.
- Adaptive trial designs offer flexibility to adjust study parameters based on accumulating data.
Purpose of the Study:
- To propose a two-stage adaptive design for clinical trials with survival endpoints using the conditional power approach.
- To provide a framework for making informed decisions about trial continuation, early termination, or sample size adjustments.
Main Methods:
- Utilized a two-stage adaptive design based on Li et al. (2002) for survival endpoints.
- Employed conditional power calculations to project future trial outcomes from interim data.
- Incorporated decision rules for early stopping due to futility or efficacy.
Main Results:
- The proposed design allows for projections of future patient needs and follow-up duration.
- Demonstrated the flexibility of the adaptive design through a case study (Coumadin Aspirin Reinfarction Study).
Conclusions:
- The conditional power approach in a two-stage design offers a flexible and efficient strategy for managing long-term clinical trials.
- This adaptive methodology can optimize resource allocation and expedite trial conclusions when appropriate.